Regencell Bioscience stock jumps 11% as RGC volatility returns ahead of Tuesday’s open
30 December 2025
1 min read

Regencell Bioscience stock jumps 11% as RGC volatility returns ahead of Tuesday’s open

NEW YORK, December 30, 2025, 05:20 ET — Premarket

  • Regencell Bioscience shares closed up nearly 11% on Monday after a wide intraday swing.
  • A fresh law-firm “investigation” notice and an older DOJ-trading probe disclosure stayed in focus.
  • Traders are watching whether the move holds once regular volume returns after the opening bell.

Regencell Bioscience Holdings Ltd shares were last indicated at $23.48 in off-hours trade ahead of Tuesday’s U.S. session.

The stock ended Monday up 10.96% at $23.48, after trading as low as $19.80 and as high as $25.50, with about 723,000 shares changing hands, MarketBeat data showed. Market capitalization was listed at roughly $11.6 billion. MarketBeat

The move stood out on a day when U.S. stocks finished lower, leaving investors cautious heading into a holiday-shortened stretch. Thin liquidity can exaggerate price swings in smaller, headline-sensitive names. Reuters

Regencell itself has not posted a new press release since Oct. 31, when it said it filed its annual report on Form 20-F, the SEC annual filing used by foreign private issuers. Regencell Bioscience –

Legal headlines have circulated again in recent days. Bronstein, Gewirtz & Grossman said on Dec. 28 it was investigating potential claims on behalf of Regencell investors, an announcement that can amplify chatter without indicating any formal finding by regulators or a court. ACCESS Newswire

In its annual report, Regencell disclosed it received correspondence and a subpoena from the U.S. Department of Justice indicating an investigation into trading in its ordinary shares, following prior volatility. SEC

After-hours trading on Monday was modest, with the stock quoted at $23.48 and up about 1.75%, according to Barron’s market data. Barron’s

Regencell is a Hong Kong-based early-stage bioscience company focused on traditional Chinese medicine formulations for neurocognitive disorders, including attention deficit hyperactivity disorder and autism spectrum disorder, according to its company profile. Reuters

On Monday, the shares opened sharply lower than the prior close — a “gap down,” meaning the first trade printed below the previous session’s closing price — before reversing higher, MarketBeat said. MarketBeat

Stock Market Today

  • Netflix Stock Poised for Rebound Ahead of Q4 Earnings and Warner Bros Acquisition
    January 19, 2026, 8:35 PM EST. Netflix (NFLX) faces a critical moment as it prepares to report Q4 2025 earnings, with expectations of 17% sales growth to $11.97 billion and a 28% rise in earnings per share (EPS) to $0.55, according to Zacks estimates. Shares have fallen 20% post a 10-for-1 stock split amid profit-taking and market softness. Meanwhile, Netflix aims to acquire Warner Bros. Discovery's studios and streaming operations in an $82.7 billion deal that would boost its subscriber base to over 370 million, intensifying competition with Disney and Amazon. Warner Bros' board favors Netflix's offer for its financial stability compared to rival bids from Paramount and Comcast, pending a planned spin-off of Warner's TV networks by late 2026. Investors watch for Netflix's rebound potential amid these strategic moves.
GST deadline tomorrow: CA body urges India to extend GSTR-9/9C as Goa chamber seeks late-fee waiver
Previous Story

GST deadline tomorrow: CA body urges India to extend GSTR-9/9C as Goa chamber seeks late-fee waiver

NIO stock today: Premarket ticks higher as CATL battery shift report meets 2026 demand warning
Next Story

NIO stock today: Premarket ticks higher as CATL battery shift report meets 2026 demand warning

Go toTop